Tesla Medical

What Tesla Medical does

Tesla Medical, operating under the legal entity Stimvia s.r.o., is a Czech healthtech company founded in 2014 and headquartered in Ostrava-Pustkovec that designs and manufactures the URIS® neuromodulation system, a medical device for the non-invasive treatment of chronic overactive bladder (OAB). The company's core technology stimulates subsurface nerves without needles, surgery, or medication, and is supported by a companion mobile application that collects patient data and enables individualized optimization of treatment parameters. Tesla Medical states URIS® is the first clinically verified neuromodulation system of its kind, with three completed clinical trials confirming effectiveness and safety for OAB.

The company targets two primary customer segments: OAB patients who have failed pharmacological therapy and wish to avoid invasive procedures, and the urologists/healthcare providers who prescribe URIS® for those patients. Its go-to-market is sales-led, relying on healthcare-provider networks as the distribution channel, and the device is commercialized under a circular-economy model in which devices are shared among patients (90% recyclable, 30% recycled materials). Revenue mechanics center on URIS® hardware sales/rental, though pricing is not publicly disclosed. As of the latest data, Tesla Medical remains pre-commercial-scale (1–10 employees), currently operates only in the Czech Republic, and is signaling an intention to enter the US market with a potential NASDAQ IPO, supported by a Series A round of approximately 100M CZK (~$4.6M) raised in August 2021 at a post-money valuation exceeding 1B CZK.

Name

Tesla Medical

Legal name

Stimvia s.r.o.

Website

https://tesla-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Tesla Medical (Stimvia s.r.o.) is a Czech healthtech company developing the URIS® non-invasive neuromodulation system to treat chronic overactive bladder in patients who have failed medication, selling via healthcare providers.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Urology Telemedicine Platforms (HLALAGAN)

Keywords

• Neuromodulation medical devices
• Non-invasive bladder treatment
• Overactive bladder therapy
• Medical device manufacturing
• Urology health technology

Headquarters

HQ city

Pustkovec

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. URIS Device Sales/Subscription: The neuromodulation devices are shared among patients as part of a circular economy model, suggesting either device rental/subscription or direct sales with device return programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Tesla Medical (operating as Stimvia s.r.o.) designs and manufactures the URIS® neuromodulation system, a non-invasive medical device that stimulates subsurface nerves to treat chronic overactive bladder (OAB) without needles, surgery, or medication. The hardware is paired with a companion mobile application that collects patient data and enables optimization of individual treatment parameters. Devices are distributed under a circular-economy model in which hardware is shared among patients.

Product overview

Tesla Medical (now operating as Stimvia) offers a single unified product called URIS®, a clinically verified neuromodulation system for treating overactive bladder (OAB). The product is a medical device that provides non-invasive nerve stimulation therapy. The offering includes the URIS® hardware device along with a companion mobile application that collects patient data and enables optimization of treatment parameters. This represents a device-plus-software approach to neuromodulation treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• URIS® Neuromodulation System

Quantifiable outcome

• One of the most effective methods in combating overactive bladder

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered minor.

• PlasseraudminorOthersLegal services firm shown in the collaboration/partners section of Stimvia's website.
• TUVminorOthersQuality and safety certification organization shown as a partner on the Stimvia website.
• Impact HubminorStrategic or Co-development PartnerAccelerator program that Stimvia is an alumnus of, providing startup support and ecosystem connections.
• Climate-KIC AcceleratorminorStrategic or Co-development PartnerClimate innovation accelerator program that Stimvia participated in, supporting sustainable technology development.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Others

• Hologic: Women's health and diagnostics major whose pelvic health franchise (formerly Cynosure/Aesthetic Link) overlaps with the urology/pelvic floor patient population Tesla Medical addresses.

Broad incumbents

• Boston Scientific: Large incumbent with the Vercise deep brain stimulation platform and broader urology/pelvic health portfolio, including sacral neuromodulation for OAB — overlapping indication with established reimbursement.
• Medtronic: Global medical device leader with InterStim sacral neuromodulation system approved for overactive bladder — the dominant incumbent Tesla Medical must compete against in OAB neuromodulation.
• NeoTract (Teleflex): Teleflex-owned urology franchise (Urolift for BPH and related technologies) — broad urology incumbent with established urologist relationships overlapping Tesla Medical's customer base.
• Laborie Medical Technologies: Global urology medical device platform (including acquired Cogentix and Uroplasty assets) covering diagnostics and OAB therapies — broad incumbent providing established hospital access Tesla Medical must enter.
• Cogentix Medical (now part of Laborie): Urology-focused medical device company with the Urgent PC percutaneous tibial neuromodulation system for OAB — overlapping neuromodulation modality and indication.

Emerging players

• Valencia Technologies (eCoin): Developer of eCoin, a minimally invasive tibial neuromodulation device for OAB — emerging competitor in the non-invasive/minimally-invasive OAB neuromodulation segment.
• StimGuard: Developer of miniature injectable wireless neuromodulation technology for urological and other indications — emerging peer using alternative neuromodulation modalities.
• BlueWind Medical: Israeli neuromodulation company developing a miniature wireless tibial neurostimulator for OAB — competing emerging player in peripheral neuromodulation for urinary indications.

Direct peers

• Axonics Modulation Technologies: Pure-play sacral and tibial neuromodulation company directly competing in OAB with FDA-approved implantable devices — closest direct comparator in modality and indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stimvia
• Xx.com/tesla_medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tesla Medical